ArticleActa pharmacologica Sinica2024

Brigatinib, a newly discovered AXL inhibitor, suppresses AXL-mediated acquired resistance to osimertinib in EGFR-mutated non-small cell lung cancer.

Rui Han et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.